VX-371

DRUG2 trials

Sponsors

Parion Sciences

Conditions

Cystic FibrosisPrimary Ciliary Dyskinesia

Phase 2

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

CompletedNCT02709109

Parion SciencesCystic Fibrosis

Start: 2016-02-29End: 2017-09-30Updated: 2021-07-29

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

CompletedNCT02871778

Parion SciencesPrimary Ciliary Dyskinesia

Start: 2016-08-31End: 2018-11-20Updated: 2021-12-16

Related Papers

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.

2023-08-3121 citations

First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers

ERJ Open Research2020-12-109 citations